Aktis scores a plenary, as do Tyra’s FGFR3 inhibitor and Arcus’s HIF-2α contender.

The group reports responses with its CD123-targeting ADC, but cash is running short.

Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.

GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.

The company reckons it can outdo Bristol’s relatlimab in first-line NSCLC.

The first approval for TAR-200 is on the horizon, setting up a challenge to Keytruda.